Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Essential thrombocythemia in young adults.

K J McIntyre1, H C Hoagland, M N Silverstein

  • 1Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905.

Mayo Clinic Proceedings
|February 1, 1991
PubMed
Summary

Essential thrombocythemia in young adults rarely causes severe complications, with most patients remaining asymptomatic. Conservative management is recommended, with anagrelide showing promise for symptomatic cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia.

British journal of haematology·2001
Same author

Treatment of systemic mast-cell disease with cladribine.

The New England journal of medicine·2001
Same author

A long-term retrospective study of young women with essential thrombocythemia.

Mayo Clinic proceedings·2001
Same author

A clinical update in polycythemia vera and essential thrombocythemia.

The American journal of medicine·2000
Same author

Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.

Blood·2000
Same author

Treatment of polycythaemia vera and essential thrombocythaemia.

Bailliere's clinical haematology·2000

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Essential thrombocythemia (ET) is a myeloproliferative neoplasm typically affecting older adults.
  • Management of ET in young adults is less defined, with concerns regarding long-term complications and treatment toxicity.
  • Thrombohemorrhagic events are characteristic of ET, but their incidence and severity in younger populations require further investigation.

Purpose of the Study:

  • To evaluate the clinical course and complications of essential thrombocythemia in a cohort of young adults.
  • To assess the long-term outcomes and safety of various treatment strategies in this patient group.
  • To provide evidence-based recommendations for the management of ET in young individuals.

Main Methods:

  • Retrospective analysis of 56 young adult patients diagnosed with essential thrombocythemia.

Related Experiment Videos

  • Data collection included patient demographics, platelet counts, clinical symptoms, thrombotic and hemorrhagic events, and treatment modalities.
  • Follow-up duration averaged 4.68 years, with a maximum of 20 years.

    • Main Results:

    • The majority of young ET patients (39/56) were asymptomatic at diagnosis.
    • Over the follow-up period, 24 patients experienced thrombotic complications, with only 3 being life-threatening.
    • Minor hemorrhagic events occurred in six patients; serious complications like myocardial infarction and cerebral infarction were rare (3 patients).
    • Two deaths occurred, unrelated to ET. No treatment-related acute leukemias were observed.
    • Anagrelide was used in 10 patients, showing potential utility for symptomatic individuals.

    Conclusions:

    • Essential thrombocythemia in young adults is associated with a low incidence of severe complications and a favorable long-term prognosis.
    • Conservative therapeutic approaches are generally advised, avoiding potentially leukemogenic agents unless clinically indicated.
    • Anagrelide may be a valuable option for managing symptomatic young patients with ET.